Quarterly Financial Information [Table Text Block] |
The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands): | | | | | | | | | | | | | | | | | | | | Quarter Ended | 2019 (Unaudited): | | March 31, | | June 30, | | September 30, | | December 31, | Total revenues (1) | | $ | 56,949 |
| | $ | 39,148 |
| | $ | 46,230 |
| | $ | 53,665 |
| Gross profit on product sales | | $ | 3,741 |
| | $ | 3,883 |
| | $ | 6,872 |
| | $ | 6,006 |
| Total operating expenses(3) | | $ | 53,983 |
| | $ | 53,125 |
| | $ | 70,767 |
| | $ | 85,727 |
| Net Income (loss) | | $ | 1,796 |
| | $ | (14,624 | ) | | $ | (25,015 | ) | | $ | (34,397 | ) | Net Income (loss) per share: | | | | | | | | | Basic | | $ | 0.01 |
| | $ | (0.10 | ) | | $ | (0.17 | ) | | $ | (0.24 | ) | Diluted | | $ | 0.01 |
| | $ | (0.10 | ) | | $ | (0.17 | ) | | $ | (0.24 | ) | Shares used in computing net income (loss) per share: | | | | | | | | | Basic | | 144,743 |
| | 145,411 |
| | 146,136 |
| | 141,046 |
| Diluted | | 147,474 |
| | 145,411 |
| | 146,136 |
| | 141,046 |
| | | Quarter Ended | 2018 (Unaudited): | | March 31, | | June 30, | | September 30, | | December 31, | Total revenues (2) | | $ | 30,872 |
| | $ | 35,202 |
| | $ | 25,556 |
| | $ | 60,232 |
| Gross profit on product sales | | $ | 3,749 |
| | $ | 3,647 |
| | $ | 5,643 |
| | $ | 5,059 |
| Total operating expenses | | $ | 54,584 |
| | $ | 55,275 |
| | $ | 51,030 |
| | $ | 60,303 |
| Net loss | | $ | (27,461 | ) | | $ | (22,893 | ) | | $ | (27,850 | ) | | $ | (2,126 | ) | Net loss per share: | | | |
|
| |
|
| |
|
| Basic | | $ | (0.19 | ) | | $ | (0.16 | ) | | $ | (0.19 | ) | | $ | (0.01 | ) | Diluted | | $ | (0.19 | ) | | $ | (0.16 | ) | | $ | (0.19 | ) | | $ | (0.01 | ) | Shares used in computing net loss per share: | |
|
| |
|
| |
|
| |
|
| Basic | | 142,656 |
| | 143,568 |
| | 143,949 |
| | 144,203 |
| Diluted | | 142,656 |
| | 143,568 |
| | 143,949 |
| | 144,203 |
|
_______________ | | (1) | Revenue for the quarter ended March 31, 2019 included $30.0 million in revenue under a collaborative arrangement from argenx. |
| | (2) | Revenues for the quarter ended December 31, 2018 included $30.0 million in revenue under a collaborative arrangement from Roche. |
(3) Total operating expenses for the quarter ended December 31, 2019 included $28.4 million restructuring charges.
|